Filing Details
- Accession Number:
- 0001209191-23-037582
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-15 19:28:58
- Reporting Period:
- 2023-06-13
- Accepted Time:
- 2023-06-15 19:28:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1601830 | Recursion Pharmaceuticals Inc. | RXRX | Biological Products, (No Disgnostic Substances) (2836) | 464099738 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1855980 | Michael Secora | C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2023-06-13 | 37,500 | $2.22 | 830,413 | No | 4 | M | Direct | |
Class A Common Stock | Disposition | 2023-06-13 | 25,000 | $9.93 | 805,413 | No | 4 | S | Direct | |
Class A Common Stock | Acquisiton | 2023-06-14 | 37,500 | $2.22 | 842,913 | No | 4 | M | Direct | |
Class A Common Stock | Disposition | 2023-06-14 | 25,000 | $10.07 | 817,913 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2023-06-13 | 37,500 | $0.00 | 37,500 | $2.22 |
Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2023-06-14 | 37,500 | $0.00 | 37,500 | $2.22 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
782,813 | 2030-03-03 | No | 4 | M | Direct | |
745,313 | 2030-03-03 | No | 4 | M | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock Option (Right to Buy) | $2.22 | 2030-03-03 | 0 | 1,500,000 | Direct | |
Class A Common Stock | Stock Option (Right to Buy) | $11.14 | 2032-02-04 | 0 | 116,684 | Direct | |
Class A Common Stock | Stock Option (Right to Buy) | $11.14 | 2022-02-04 | 2032-02-04 | 0 | 3,914 | Direct |
Class A Common Stock | Stock Option (Right to Buy) | $8.55 | 2033-02-01 | 0 | 404,857 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2030-03-03 | 0 | 1,500,000 | Direct |
2032-02-04 | 0 | 116,684 | Direct |
2032-02-04 | 0 | 3,914 | Direct |
2033-02-01 | 0 | 404,857 | Direct |
Footnotes
- Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023.
- Includes 2,754 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023.
- This transaction was executed in multiple trades at prices ranging from $9.59 to $10.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $9.63 to $10.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.